Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,458 total articles
HighPeak Energy beat Q3 estimates with $0.32 EPS and $256.82M revenue, earning a fresh ratings lift. Fundamentals and valuation now create a pragmatic long trade: entry near $7.46, stop at $6.20, target $11.00 over the next 45 trading days, with clear catalysts and defined risks.
Broadcom ($AVGO) pulled back sharply from 2026 highs amid broad tech weakness and AI regulatory chatter. The business mixes semiconductor exposure to AI infrastructure with a sticky infrastructure software franchise, generating $39.4B of free cash flow and industry-leading returns on equity. With a market cap near $1.67T and valuation back below th…
Orrstown Financial Services (ORRF) reported a solid Q3 with $66.7M in revenue, $22.8M in net income and EPS of $1.17, while management is actively repositioning the securities portfolio to lift future yields. At roughly $860M market cap, low leverage and a P/B near 1.4 leave room for upside. This trade plan targets a disciplined long into a 180-tra…
Broadcom is one of the best cash-generating plays in semiconductors with direct exposure to AI data-center demand through custom accelerators and networking silicon. The company trades at a premium - market cap ~$1.67T and a P/E above 40 - yet still earns enormous free cash flow ($39.4B). Recent political pressure on AI data-center approvals and an…
TransMedics beat Q3 estimates and continues to scale service revenue and international adoption. With fleet-wide satellite connectivity scheduled for 2027 and a Gen 3.0 product roadmap, the stock looks set for another leg higher—provided margin pressure stabilizes and legal/operational risks don’t derail execution. This is a long trade plan with cl…
AstraZeneca's oncology franchise and expanding partnership pipeline appear to be offsetting pressures in the cardiorenal/metabolism franchise. With positive partner readouts and visible cash flow to fund launches, the risk-reward favors a long trade into the next set of oncology catalysts.
AppLovin (APP) surged on a blowout Q3 that showed the company's AI-driven ad stack lifting revenue and margins. The business generates large free cash flow and is guiding continued high-margin growth; I think the stock can climb further over the next several months if execution holds. This is a tactical long with a clear entry, target and stop cali…
TTM Technologies is trading well below its recent peak despite clear AI/data-center momentum and a growing aerospace & defense backlog. Q3 showed $1.2B in revenue, record margins, and a $2B defense backlog. Short-term supply hiccups and conservative Q4 guidance have created an entry point. This trade targets upside as capacity expansion and potenti…
AMD is trading with strong momentum after a $2.5B Anthropic commitment and a record quarterly revenue print. Fundamentals—low net leverage, meaningful free cash flow and accelerating data-center traction—support another leg higher even as the stock remains richly valued. This trade idea favors a mid-term (45 trading days) long, sized to tolerate vo…
ICF International (ICFI) looks like an actionable swing trade: solid backlog ($3.5B), beat on Q3 margins and EPS, and attractive cash flow metrics argue for upside toward prior highs. Enter around the current price for a mid-term rebound to $100, but use a disciplined stop — political spending cycles and commercial softness could push shares back t…
<p>Webtoon (WBTN) is at a crossroads. A new, higher-profile Marvel collaboration has put a visible deadline on management's turnaround plan: either show meaningful traffic-to-revenue conversion in the next several months or risk sentiment permanently resetting lower. This trade pins a directional stake to the outcome — a defined-entry long that bal…
Micron's share price is being punished on fears the AI memory boom will fade. Fundamentals - $820B market cap, EPS of $75.10, free cash flow near $59B, and a rock-solid balance sheet - argue this is a buy-the-panic setup. This trade idea lays out an entry, stop, and target with a clear horizon and risk plan.
Village Farms looks cheap relative to its recent operational momentum. A clearer path into Texas retail and continued European export strength — combined with a solid liquidation runway and attractive valuation (EV/EBITDA ~5.6, P/E ~14.5) — justify an upgrade to Buy. Enter at $2.70 with a $4.00 target over a 180-trading-day horizon and a $2.10 stop…
I’m upgrading Cisco (CSCO) to a tactical long after underestimating the company’s exposure to AI infrastructure. Strong order momentum, meaningful AI revenue guidance and a healthy cash flow profile create an asymmetric risk-reward over the next 45 trading days. Entry $99.75, target $115.00, stop $92.00.
Dycom's recent pullback has created an actionable long entry. The company pairs a predictable communications backlog with a fast-growing, high-margin Building Systems business that is driving upgraded guidance. At a market cap near $6.6B and an EV/EBITDA of ~9.9x, Dycom looks attractively priced against its free cash flow generation and peer multip…
BILL Holdings is showing a clear inflection in profitability even as revenue growth lags. EPS beat and management guidance point to improving operating leverage driven by payment volumes, AI efficiencies and cross-sell. The trade is a long with a defined entry at current levels, a stop to protect against renewed top-line pressure, and a target that…
Forward Air (FWRD) disappointed investors with execution around an Omni-related acquisition, but the Q3 earnings beat, meaningful free cash flow, sub-1x price-to-sales and an attractive EV/EBITDA support a tactical long. This trade plan lays out entry, stop and target levels and the scenarios that would change the thesis.
Atlassian reported strong Q1 fiscal 2027 results with 24% revenue growth and material margin expansion driven by cloud and AI adoption. The stock is technically oversold and offers a tactical long opportunity around $150 with a $200 target over the next 180 trading days, but investors must respect valuation and execution risks.
Grab is trading near my 2024 entry price after a strong move in 2026 driven by margin expansion and AI efficiencies. I downgrade my long-term rating to Neutral but outline a tactical swing long: entry $3.30, stop $2.70, target $4.20 over ~45 trading days if macro and regional dynamics hold.
U.S. Bancorp (USB) looks attractive right now. The bank trades at ~12x earnings, yields roughly 3.5% and sits above several short- and medium-term moving averages while generating meaningful free cash flow. With higher-for-longer rates and floating-rate liabilities and assets that reprice in the current environment, investors can pair modest upside…
Western Digital has transformed from a cyclical disk maker into a high-margin infrastructure supplier thanks to higher-capacity HDDs and favorable pricing. With Q1 gross margin at 58.1% and Q2 guidance pointing to 60-61%, low leverage and strong free cash flow, WDC is a tradeable long for investors wanting AI-era storage exposure. I outline a clear…
We upgrade The Hartford (HIG) to a buy and propose a long trade. Favorable investment yield dynamics, a Q3 beat, and attractive valuation (P/E ~8, EV/EBITDA ~7) create asymmetric upside to $155; protect with a $128 stop.
NWBI offers a constructive risk-reward: a $2.25B regional bank paying a 5.2% yield, with Q3 revenue growth, improving efficiency metrics and room for modest multiple expansion. This trade plan lays out a long entry at $15.35, a stop at $14.60, and a target of $17.15 over a 180 trading-day horizon.
APA Corporation is posting real cash-flow improvements: management raised 2026 free cash flow to $2.9B, delivered $500M in annualized cost savings early, and is dialing down leverage. With GranMorgu Suriname development adding optionality and valuation trading below peers on multiple cash metrics, we recommend a long trade for precise risk/reward.
Septerna (SEPN) is a clinical-stage biotech trading at $52.09 with a market cap near $2.4B. The stock has run into its 52-week high but still looks actionable ahead of an expected SEP-479 SAD/MAD readout in Q1 2027. Positive safety/pharmacology data would likely unlock multiple re-rating scenarios given the company’s cash runway and GPCR-focused pl…
